July 2018
Volume 59, Issue 9
ARVO Annual Meeting Abstract  |   July 2018
Neoplastic routes to autoimmunity: Disease vs therapy
Author Affiliations & Notes
  • Bahram Bodaghi
    Ophthalmology, Pitie - Salpetriere Hospital, Paris, France
  • Footnotes
    Commercial Relationships   Bahram Bodaghi, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4406. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Bahram Bodaghi; Neoplastic routes to autoimmunity: Disease vs therapy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4406. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : It is generally accepted that all roads may lead to autoimmunity. Various ocular neoplastic conditions may masquerade as uveitis with diagnostic delay and sight or life-threatening complications. Different studies based on animal models but also affected patients have demonstrated cytokine profiles explaining disease pathophysiology, malignant tissue infiltration and secondary uveitis after efficient chemotherapy. More recently, immune-related ocular toxicities in solid tumor patients treated with biologic agents such as immune checkpoint or B-Raf inhibitors have emphasized a new challenging situation, which must be considered by oncologists and ophthalmologists involved in the care of these patients. Uveitis and dry eye syndrome are particularly important to consider in this particular setting. Direct action on neoplastic cells, alteration of the immune network or direct toxicity are potential mechanisms to consider. Temporary drug withdrawal and corticosteroids may control these immune-related ocular adverse events.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.